Predicting Cancer Risk With Digital and Molecular Markers
NCT ID: NCT06962670
Last Updated: 2025-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1250 participants
INTERVENTIONAL
2024-09-14
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT01000883
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
NCT03709134
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
NCT02078570
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Molecular Signature for Breast Cancer
NCT05724407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group (subjects with known pre-existing or current cancer diagnosis)
The case group will consist of subjects with a known pre-existing or current cancer diagnosis, including breast cancer, lung cancer, colorectal cancer or gynecologic cancer
Biomaterial collection
All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
BayPass mobile application
All subjects will be asked to use the study-specific mobile application "BayPass" to complete questionnaires and provide results from screening examinations over a course of 12 months.
Control group (healthy subjects)
The control group will consist of healthy subjects with no history of cancer
Biomaterial collection
All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
BayPass mobile application
All subjects will be asked to use the study-specific mobile application "BayPass" to complete questionnaires and provide results from screening examinations over a course of 12 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomaterial collection
All subjects will be asked to provide biomaterial (blood or saliva) for bio marker screening and analysis. Additional biomaterial (breath, urin, stool) is optional.
BayPass mobile application
All subjects will be asked to use the study-specific mobile application "BayPass" to complete questionnaires and provide results from screening examinations over a course of 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Written informed consent for study participation and processing of personal data
3. Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes
Additional inclusion criterion for case group:
4. Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)
Exclusion Criteria
2. Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter A. Fasching
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias W. Beckmann, Prof. Dr. med.
Role: STUDY_DIRECTOR
Head of Department of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
DigiOnko Präventionsmobil
Please Refer to Project Homepage For Details (see Link Below), Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
On this project homepage you can check where the next stop of the DigiOnko Präventionsmobil will be
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PräDigt-08/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.